I. Dubuc

发表

Centrally administered [D-Trp11]neurotensin, as well as neurotensin protected from inactivation by thiorphan, modifies locomotion in rats in a biphasic manner

J. Costentin, P. Kitabgi, D. Nouel, 1990, Peptides.

Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats.

J. Costentin, P. Protais, I. Dubuc, 1983, European journal of pharmacology.

Behavioral and neurochemical profiles of discriminant benzamide derivatives. Comment

M. Martres, P. Sokoloff, J. Schwartz, 1987 .

JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse.

J. Costentin, P. Kitabgi, J. Martinez, 1992, European journal of pharmacology.

Data set describing the in vitro biological activity of JMV2009, a novel silylated neurotensin(8–13) analog

Jean Martínez, R. Fanelli, P. Tétreault, 2020, Data in brief.

Effects of thiorphan, bestatin and a novel metallopeptidase inhibitor JMV 390-1 on the recovery of neurotensin and neuromedin N released from mouse hypothalamus

J. Costentin, P. Kitabgi, Jean Martinez, 1992, Neuroscience Letters.

Dopaminergic Behavioral Responses and Classes of Binding Sites Distinguished by Discriminant Benzamide Derivatives

M. Martres, M. Bouthenet, N. Salès, 1986 .

Indenylnickel Imidato Complexes: Synthesis, Characterization, and Reactivities

D. Zargarian, F. Bélanger-Gariépy, I. Dubuc, 1999 .

STRUCTURAL AND NMR STUDIES OF INDENYL HAPTICITY AND ROTATIONAL BARRIERS INTHE COMPLEXES (ETA -1-R-INDENYL)NI(PPH3)(X) (R = H, ME; X = CL, ME)

T. Huber, D. Zargarian, M. Bayrakdarian, 1997 .

Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog.

Jean Martínez, R. Fanelli, P. Tétreault, 2020, European journal of pharmacology.

Identification of the Receptor Subtype Involved in the Analgesic Effect of Neurotensin

J. Costentin, P. Kitabgi, E. Honoré, 1999, The Journal of Neuroscience.

Antagonism of the apomorphine-induced yawning by “atypical” neuroleptics

J. Costentin, P. Protais, I. Dubuc, 1982, Neuropharmacology.

The partial agonist properties of levocabastine in neurotensin-induced analgesia.

J. Costentin, I. Dubuc, S. Remande, 1999, European journal of pharmacology.

Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice

J. Costentin, P. Bredeloux, I. Dubuc, 2006, Behavioural Brain Research.

FUNCTIONAL AND PHARMACOLOGICAL ASPECTS OF CENTRAL NEUROPEPTIDERGIC TRANSMISSION MEDIATED BY NEUROTENSIN AND NEUROMEDIN N

A. Beaudet, J. Woulfe, J. Costentin, 1992, Clinical neuropharmacology.

Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier.

Jean Martínez, J. Costentin, F. Cavelier, 2008, Journal of medicinal chemistry.

In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.

A. Brouard, J. Costentin, W. Rostène, 1994, The Journal of pharmacology and experimental therapeutics.

Synthesis and analgesic effects of N-[3-[(hydroxyamino) carbonyl]-1-oxo-2(R)-benzylpropyl]-L-isoleucyl-L-leucine, a new potent inhibitor of multiple neurotensin/neuromedin N degrading enzymes.

F. Checler, H. Fulcrand, A. Aumelas, 1993, Journal of medicinal chemistry.

Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin n

A. Coquerel, J. Costentin, I. Dubuc, 1988, Neurochemistry International.

Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission

J. Costentin, P. Bredeloux, I. Dubuc, 2007, British journal of pharmacology.

Neuropeptide Y and α-MSH Circadian Levels in Two Populations with Low Body Weight: Anorexia Nervosa and Constitutional Thinness

B. Estour, N. Germain, B. Galusca, 2015, PloS one.

Effect of food deprivation on the hypothalamic gene expression of the secretogranin II-derived peptide EM66 in rat

N. Chartrel, Y. Anouar, J. Leprince, 2017, Neuroreport.

A potential role for the secretogranin II‐derived peptide EM66 in the hypothalamic regulation of feeding behaviour

N. Chartrel, Y. Anouar, J. Leprince, 2017, Journal of neuroendocrinology.

The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes

P. Soubrié, J. Terranova, G. Fur, 1994, British journal of pharmacology.

Developmental changes of (3)H-labelled mu-opioid receptors in brainstems of intra-uterine growth-restricted rats.

L. Cazin, A. Coquerel, J. Costentin, 2001, Brain research. Developmental brain research.

Localization of neurotensin NTS2 receptors in rat brain, using [3H]levocabastine

I. Dubuc, Marie-Liesse Asselin, Antoine Coquerel, 2001, Neuroreport.

Tolerance to the hypothermic but not to the analgesic effect of [d-Trp11]neurotensin during the semichronic intracerebroventricular infusion of the peptide in rats

J. Costentin, C. Suaudeau, C. Pain, 1994, Peptides.

Calcium-dependent release of neuromedin N and neurotensin from mouse hypothalamus

J. Costentin, P. Kitabgi, D. Nouel, 1990, Neuropeptides.